Diabetic Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000
Buy Report

Published: April 29, 2022 Report Code: GMDGDHC22134IDB-ST

Select Item

Diabetic Nephropathy Pipeline Drugs Market Overview

Diabetic Nephropathy pipeline drugs market research report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.

Key Targets in the Diabetic Nephropathy Pipeline Drugs Market

In the Diabetic Nephropathy pipeline drugs market, the key targets are Cannabinoid Receptor 1, Nuclear Factor Erythroid 2 Related Factor 2, Endothelin 1 Receptor, Sodium/Glucose Cotransporter 2, Transforming Growth Factor Beta 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, and C-C Chemokine Receptor Type 2. Cannabinoid Receptor 1 has the highest pipeline products.

Diabetic Nephropathy Pipeline Drugs Market, by Targets

Diabetic Nephropathy Pipeline Market, by Targets

For more target insights, download a free report sample

Key MoA in the Diabetic Nephropathy Pipeline Market

The key MoA in the Diabetic Nephropathy pipeline market are Cannabinoid Receptor 1 Antagonist, Endothelin 1 Receptor Antagonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Sodium/Glucose Cotransporter 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, and C-C Chemokine Receptor Type 2 Antagonist. Cannabinoid Receptor 1 Antagonist has the highest pipeline products.

Diabetic Nephropathy Pipeline Market, by MoA

Diabetic Nephropathy Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Diabetic Nephropathy Pipeline Market

The key RoA in the Diabetic Nephropathy pipeline market are oral, intravenous, subcutaneous, parenteral, topical, intraarterial, intravitreal, nasogastric, and ophthalmic. Oral has the highest pipeline products.

Diabetic Nephropathy Pipeline Market, by RoA

Diabetic Nephropathy Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Diabetic Nephropathy Pipeline Drugs Market

In the Diabetic Nephropathy pipeline drugs market, the key molecule types are small molecule, monoclonal antibody, cell therapy, synthetic peptide, fusion protein, antisense oligonucleotide, biologic, antisense RNAi oligonucleotide, peptide, recombinant peptide, and recombinant protein. Small molecule has the highest pipeline products.

Diabetic Nephropathy Pipeline Drugs Market, by Molecule Types

Diabetic Nephropathy Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Diabetic Nephropathy Pipeline Market

The key companies in the Diabetic Nephropathy pipeline market are AstraZeneca Plc, Boehringer Ingelheim International GmbH, Goldfinch Bio Inc, Scohia Pharma Inc, Serodus ASA, ZyVersa Therapeutics Inc, and Aadi Bioscience Inc. AstraZeneca Plc has the highest number of pipeline products.

Diabetic Nephropathy Pipeline Market, by Companies

Diabetic Nephropathy Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets Cannabinoid Receptor 1, Nuclear Factor Erythroid 2 Related Factor 2, Endothelin 1 Receptor, Sodium/Glucose Cotransporter 2, Transforming Growth Factor Beta 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, and C-C Chemokine Receptor Type 2
Key MoA Cannabinoid Receptor 1 Antagonist, Endothelin 1 Receptor Antagonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Sodium/Glucose Cotransporter 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, and C-C Chemokine Receptor Type 2 Antagonist
Key RoA Oral, Intravenous, Subcutaneous, Parenteral, Topical, Intraarterial, Intravitreal, Nasogastric, and Ophthalmic
Key molecule types Small Molecule, Monoclonal Antibody, Cell Therapy, Synthetic Peptide, Fusion Protein, Antisense Oligonucleotide, Biologic, Antisense RNAi Oligonucleotide, Peptide, Recombinant Peptide, and Recombinant Protein
Key companies AstraZeneca Plc, Boehringer Ingelheim International GmbH, Goldfinch Bio Inc, Scohia Pharma Inc, Serodus ASA, ZyVersa Therapeutics Inc, and Aadi Bioscience Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Aadi Bioscience Inc
AIBIOS Co Ltd
Akebia Therapeutics Inc
Algomedix Inc
Anagenics Ltd
APT Therapeutics Inc
AptaBio Therapeutics Inc
Araim Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
Betagenon AB
Bird Rock Bio Inc
BLR Bio LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Caladrius Biosciences Inc
CCRP Therapeutics GmbH
Certa Therapeutics Pty Ltd
ChemoCentryx Inc
Chinook Therapeutics Inc
Corbus Pharmaceuticals Inc
CSL Ltd
Curacle Co Ltd
Daiichi Sankyo Co Ltd
DiaMedica Therapeutics Inc
Dimerix Ltd
Frontbio Co Ltd
Future Medicine Co Ltd
GenKyoTex SA
Gilead Sciences Inc
Glycadia Inc
Gmax Biopharm LLC
GNI Group Ltd
Goldfinch Bio Inc
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Guangzhou Nanxin Pharmaceutical Co Ltd
Hua Medicine Shanghai Ltd
Inovio Pharmaceuticals Inc
InSilico Medicine
Inversago Pharma Inc
Johnson & Johnson
Landos Biopharma Inc
MediPost Co Ltd
Merck & Co Inc
Mesoblast Ltd
Mitsubishi Tanabe Pharma Corp
Nanjing Aimeifei Biomedical Technology Co Ltd
Novartis AG
Novo Nordisk AS
Ono Pharmaceutical Co Ltd
Orbsen Therapeutics Ltd
PhytoHealth Corp
Poxel SA
Praetego Inc
ProKidney LLC
RAGE Biotech Pty Ltd
Reata Pharmaceuticals Inc
Rebus Holdings Inc
Scohia Pharma Inc
Secarna Pharmaceuticals GmbH & Co KG
Serodus ASA
Shanghai Alebund Pharmaceuticals Ltd
Shanghai Pharmaceutical Group Co Ltd
siRNAgen Therapeutics Corp
Slate Bio Inc
Sulfateq BV
Unicyte AG
Vidasym Inc
Wuhan Hamilton Bio-technology Co Ltd
Wuhan LL Science and Technology Development Co Ltd
XORTX Therapeutics Inc
ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Diabetic Nephropathy – Overview

Diabetic Nephropathy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Diabetic Nephropathy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Nephropathy – Companies Involved in Therapeutics Development

Diabetic Nephropathy – Drug Profiles

Diabetic Nephropathy – Dormant Projects

Diabetic Nephropathy – Discontinued Products

Diabetic Nephropathy – Product Development Milestones

Featured News & Press Releases

Feb 28, 2022: Goldfinch Bio announces positive preliminary data from phase 2 clinical trial evaluating GFB-887 as a precision medicine for patients with focal segmental glomerular sclerosis (FSGS)

Nov 08, 2021: Goldfinch Bio showcases biology, genetic and clinical programs at ASN Kidney Week demonstrating leadership in precision medicines for kidney diseases

Sep 17, 2021: adMare Portfolio Company, Inversago Pharma initiates a phase 1 clinical trial on INV-202, a next generation peripherally-acting CB1 Blocker

Sep 07, 2021: Inversago Pharma initiates a phase 1 clinical trial on INV-202, a next generation peripherally-acting CB1 blocker

Sep 01, 2021: XORTX announces grant of European patent supporting diabetic nephropathy

Aug 28, 2021: Bayer announces KERENDIA (finerenone) reduces the risk of cardiovascular outcomes in new phase III FIGARO-DKD study in adults with chronic kidney disease (Stages 1-4) associated with type 2 diabetes

Aug 17, 2021: Bayer to present late breaking data from Phase III FIGARO-DKD (finerenone) studies

Aug 02, 2021: Shanghai Pharmaceuticals SPH3127 tablets new indications received phase II clinical trial approval notice

Jul 27, 2021: Goldfinch Bio announces upcoming presentations at the 13th International Podocyte Conference

Jun 22, 2021: Caladrius Biosciences to assess its CLBS201 CD34+ cell therapy in diabetic kidney disease

May 13, 2021: Goldfinch Bio initiates phase 1 clinical trial of GFB-024, a novel precision medicine product candidate for patients with severe insulin resistant Diabetic Nephropathy (DN)

Mar 31, 2021: Mitsubishi Tanabe Pharma wins patent infringement lawsuit of Canagliflozin Hydrate in the U.S. district court

Feb 26, 2021: Canagliflozin (TA-7284) has been approved in Taiwan for diabetic nephropathy

Sep 21, 2020: New study offers hope for patients with diabetes and advanced kidney disease

Sep 08, 2020: Publication of a preclinical study: SCO-792, an enteropeptidase inhibitor, may be a new therapeutic agent for diabetic kidney disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

Diabetic Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Metabolic Disorders reports
Pharmaceuticals
New
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Diabetic Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Diabetic Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more